VIVS Stock Chart & Stats
$1.61
--
Market closed
$1.61
--
Day’s Range― - ―
52-Week Range$0.78 - $5.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)129.05K
Market Cap
$2.11M
Enterprise Value-$764.00K
Total Cash (Recent Filing)$4.29M
Total Debt (Recent Filing)$577.00K
Price to Earnings (P/E)―
Beta1.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding2,607,962
10 Day Avg. Volume56,092
30 Day Avg. Volume129,049
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-3.37
Price to Sales (P/S)28.25
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.36
Enterprise Value/Revenue-5.38
Enterprise Value/Gross Profit-5.38
Enterprise Value/Ebitda0.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9
Revenue Forecast (FY)$232.00K
VivoSim Labs News
VIVS FAQ
What was VivoSim Labs’s price range in the past 12 months?
VivoSim Labs lowest stock price was $0.78 and its highest was $5.30 in the past 12 months.
What is VivoSim Labs’s market cap?
VivoSim Labs’s market cap is $2.11M.
When is VivoSim Labs’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VivoSim Labs’s earnings last quarter?
Currently, no data Available
Is VivoSim Labs overvalued?
According to Wall Street analysts VivoSim Labs’s price is currently Overvalued.
Does VivoSim Labs pay dividends?
VivoSim Labs does not currently pay dividends.
What is VivoSim Labs’s EPS estimate?
VivoSim Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VivoSim Labs have?
VivoSim Labs has 2,607,962 shares outstanding.
What happened to VivoSim Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VivoSim Labs?
Currently, no hedge funds are holding shares in VIVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VivoSim Labs
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Technical Analysis
Palisade Bio
―
Alaunos Therapeutics
―
Indaptus Therapeutics
―
Xenetic Biosciences
―
Longevity Health Holdings
―
Ownership Overview
3.90% Insiders
1.55% Mutual Funds
<0.01% Other Institutional Investors
93.95% Public Companies and
Individual Investors